TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 178687
Drug: Chronic E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic E administration (ethinyl estradiol 0.5 mg/day for 7 to 70 days)
Study: 178687
Drug: iv administration
Normalized name: IV Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv administration of E (bolus injection of 25 mg conjugated estrogens, USP)
Study: 178687
Drug: iv administration
Normalized name: IV Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv administration of normal saline
Study: 27771320
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water injections (SWI)
Study: 18714500
Drug: Systane treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systane treatment
Study: 30712496
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion lignocaine
Study: 26656722
Drug: Tele-thrombolysis (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele-thrombolysis (IV rt-PA administration in ER)
Study: 27062408
Drug: K-877 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 0.025 mg BID
Study: 27062408
Drug: K-877 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 0.05 mg BID
Study: 27062408
Drug: K-877 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 0.1 mg BID
Study: 27062408
Drug: K-877 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 0.2 mg BID
Study: 16893712
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg warfarin initiation nomogram
Study: 11160543
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (two 7000‐microg retinol equivalent doses)
Study: 8155452
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg and PCA containing morphine
Study: 8155452
Drug: Droperidol 0.05
Normalized name: fentanyl citrate/droperidol 0.05-2.5MG INJECTION VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.05 mg mg‐1 of morphine in PCA
Study: 8155452
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo and PCA containing morphine)
Study: 29684092
Drug: Short cycle
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short cycle therapy (SCT; 5 days on, 2 days off ART)
Study: 29684092
Drug: Short cycle
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short cycle therapy (SCT)
Study: 26460894
Drug: Competence and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Competence and Adherence Scale for Cognitive Behavioral Therapy (CAS‐CBT)
Study: 25578377
Drug: Anthracycline-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-based chemotherapy (6 cycles)
Study: 24434090
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing
Study: 24434090
Drug: Fast titration
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast titration
Study: 24434090
Drug: Stimulant-naive patients
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant-naive patients
Study: 24434090
Drug: Twice-daily dosing
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dosing
Study: 20625120
Drug: Control (Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Arm A): four cycles of mitomycin (8 mg/m(2) on day 1)/vindesine (3 mg/m(2) on days 1, 8)/cisplatin (80 mg/m(2) on day 1) plus TRT 60 Gy
Study: 20625120
Drug: Experimental (Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental (Arm B): weekly irinotecan (20 mg/m(2))/carboplatin (AUC 2) for 6 weeks plus TRT 60 Gy, followed by two courses of irinotecan (50 mg/m(2) on days 1, 8)/carboplatin (AUC 5 on day 1)
Study: 20625120
Drug: Experimental (Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental (Arm C): weekly paclitaxel (40 mg/m(2))/carboplatin (AUC 2) for 6 weeks plus TRT 60 Gy, followed by two courses of paclitaxel (200 mg/m(2) on day 1)/carboplatin (AUC 5 on day 1)
Study: 17330626
Drug: Metronidazole topical
Normalized name: MetroNIDAZOLE Topical
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole topical gel 0.75%
Study: 15025849
Drug: PDRN ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDRN ointment
Study: 15025849
Drug: Control (non-adherent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-adherent gauzes and bulky gauzes with cloramine solution)
Study: 11448900
Drug: Melanoma vaccine
Normalized name: melanoma vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanoma vaccine (40 microg, bound to alum as an adjuvant)
Study: 11448900
Drug: Placebo vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaccine (human albumin, bound to alum as an adjuvant)
Study: 11448900
Drug: Melanoma vaccine
Normalized name: melanoma vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanoma vaccine
Study: 8275733
Drug: 167-ml chamber
Normalized name: POCKET CHAMBER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 167-ml chamber device (Device A)
Study: 8275733
Drug: 700-ml chamber
Normalized name: POCKET CHAMBER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700-ml chamber device (Device B)
Study: 3050853
Drug: 25 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 micrograms dose of H. influenzae type b PRP vaccine
Study: 3050853
Drug: 12.5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 micrograms dose of H. influenzae type b PRP vaccine (used in 1974)
Study: 17894054
Drug: Higher dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosage of pizotyline
Study: 17894054
Drug: Lower dosage
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dosage of pizotyline
Study: 27225761
Drug: Norepinephrine transporter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine transporter blocker atomoxetine
Study: 20180694
Drug: Sootshekhar Rasa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sootshekhar Rasa (250 mg) plus Sitopaladi Churna (400 mg) daily for 90 days
Study: 20180694
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid tablet for 90 days
Study: 16996826
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg loading dose followed by 10 mg daily
Study: 16996826
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg loading dose followed by 75 mg daily
Study: 30281924
Drug: Fentanyl (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (300 μg oral dose)
Study: 23163910
Drug: linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 5 mg and 10 mg
Study: 16452736
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate at a dosage of 10 mg/day for six months
Study: 15212653
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy (0.017 mg/kg/week for 1 month, then 0.033 mg/kg/week)
Study: 15212653
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy (open study after 6 months)
Study: 9215240
Drug: Injections of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections of peanut extract (0.5 ml of 1:100 wt/vol peanut extract)
Study: 9215240
Drug: Injections of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections of peanut extract
Study: 8305355
Drug: Prochlorperazine 10
Normalized name: prochlorperazine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 10 mg t.d.s.
Study: 11641293
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein supplement to increase protein intake to 25% energy
Study: 11641293
Drug: Psyllium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium supplement to provide an additional 12 g soluble fiber/d
Study: 11641293
Drug: Both protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both protein and fiber supplements
Study: 2686456
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptives (ethinyl estradiol and levonorgestrel)
Study: 2686456
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptives (ethinyl estradiol and norethindrone)
Study: 2686456
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptives (all formulations)
Study: 2686456
Drug: All triphasic
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All triphasic oral contraceptives
Study: 30051179
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa treatment
Study: 28676236
Drug: Treatment (nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (nifedipine controlled-release tablet)
Study: 21224234
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of l‐carnitine‐l‐tartrate and 80 g of CHO (Carnitine)
Study: 21224234
Drug: 80 g
Normalized name: PEG-80 GLYCERYL COCOATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g of CHO (Control)
Study: 15333727
Drug: 5 d/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 d/wk iron supplementation (Ferrous sulfate 300 mg)
Study: 15333727
Drug: 1 d/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 d/wk iron supplementation (Ferrous sulfate 300 mg)
Study: 7866806
Drug: sulglycotide 200
Normalized name: sulglicotide
DrugBank: Sulglicotide (DB13299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulglycotide 200 mg twice daily
Study: 30447565
Drug: Sertraline -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline - Clinical Management (CM)
Study: 30447565
Drug: Pill Placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill Placebo - Clinical Management (CM)
Study: 30447565
Drug: All conditions
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All conditions (IPT, Sertraline-CM, Pill Placebo-CM)
Study: 29478425
Drug: Day hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day hospital mentalization-based treatment (MBT-DH)
Study: 29478425
Drug: Specialist treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialist treatment as usual (S-TAU)
Study: 24612221
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg BID)
Study: 17903157
Drug: Endovenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous laser (EVL) treatment with a 980‐nm diode, plus clinical treatment
Study: 17903157
Drug: Clinical treatment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical treatment (elastic or inelastic compression therapy)
Study: 11692348
Drug: Tramadol drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol drops 3 mg/kg plus oral midazolam 0.5 mg/kg
Study: 11692348
Drug: Tramadol drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol drops 3 mg/kg
Study: 7564670
Drug: Terlipressin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin combined with glyceryl trinitrate (TER-GTN), intravenous injection (1 to 2 mg)
Study: 7564670
Drug: Double-placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-placebo injection
Study: 31651877
Drug: High-dimensional test
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dimensional test for treatment effects
Study: 31651877
Drug: Conventional test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional test for treatment effects
Study: 19388972
Drug: Nateglinide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (120 mg three times daily)
Study: 3525684
Drug: Adjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant systemic antibiotic therapy
Study: 23939512
Drug: Yohimbine HCL
Normalized name: yohimbine HCl
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine HCL (single administration paired with the first session of imaginal exposure)
Study: 22110589
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml orange juice daily for 4 weeks
Study: 22110589
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml control drink plus hesperidin daily for 4 weeks
Study: 22110589
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml control drink and placebo daily for 4 weeks
Study: 16923110
Drug: Control (other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (other therapies)
Study: 10912889
Drug: 10% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% maltodextrin solution (Md)
Study: 3919917
Drug: Intravenous hyperalimentation
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hyperalimentation (IVH) for 30 days
Study: 27010683
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of study medication
Study: 27010683
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day of study medication (control)
Study: 17030973
Drug: Culturally proficient
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally proficient 14-week diet/physical activity intervention (three times weekly)
Study: 15295782
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsules with vitamin E TPGS (5 mg strength)
Study: 15295782
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsules without vitamin E TPGS (5 mg strength)
Study: 11890241
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (active patient participation in treatment choice)
Study: 11890241
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standardized treatment protocols)
Study: 7530121
Drug: Alfuzosin (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin (long-term treatment)
Study: 3057844
Drug: Propafenone 337.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 337.5 mg/day
Study: 3057844
Drug: Propafenone 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 900 mg/day
Study: 3057844
Drug: Propafenone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (all doses)
Study: 22402204
Drug: Interferon beta
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta and low‐dose azathioprine
Study: 22402204
Drug: Interferon beta,
Normalized name: Interferon beta, recombinant human
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta, azathioprine and low‐dose prednisone
Study: 18164827
Drug: Drug skill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug skill refusal techniques
Study: 16357552
Drug: Low-dose botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose botulinum toxin (100 units) with short-term electrical stimulation
Study: 16357552
Drug: High-dose botulinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose botulinum toxin (400 units)
Study: 11305382
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate fatty cream, applied twice weekly for 6 months
Study: 11305382
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate fatty cream
Study: 8975837
Drug: Postoperative low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Postoperative low-dose aprotinin (2 million kallikrein inactivator units)
Study: 1535579
Drug: Roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 150 mg
Study: 1535579
Drug: Roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 300 mg
Study: 6142218
Drug: Amantadine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (100 mg daily)
Study: 30190053
Drug: Unified Protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified Protocol (UP) treatment, 12 weekly sessions
Study: 21982055
Drug: 755 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 755 nm laser therapy
Study: 21982055
Drug: Tacrolimus cream
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus cream
Study: 15909439
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (moist gauze)
Study: 10537958
Drug: Continuous intrathecal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intrathecal baclofen infusion via a subcutaneously implanted programmable pump (SynchroMed, Medtronic)
Study: 1830108
Drug: Isradipine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 5.0 mg once daily
Study: 24837444
Drug: Weight change
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight change among treatment groups
Study: 22592504
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort (SJW) 900-1500 mg
Study: 22592504
Drug: Sertraline 50-100
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50-100 mg
Study: 19891698
Drug: Subdermal testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subdermal testosterone implants (TI)
Study: 22884063
Drug: 100 mg/d
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/d oral progesterone
Study: 22884063
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d oral progesterone
Study: 22884063
Drug: 300 mg/d
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/d oral progesterone
Study: 22884063
Drug: 400 mg/d
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d oral progesterone
Study: 2672062
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy at high intensity (2000 lux)
Study: 2672062
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy at low intensity (300 lux)
Study: 30859660
Drug: Turmeric (2,100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric (2,100 mg powdered rhizome of turmeric daily)
Study: 16582864
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid (2.2 g, single dose 30 min before surgery)
Study: 16582864
Drug: Cefazolin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (2 g, single dose 30 min before surgery)
Study: 12837854
Drug: CP-346086 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-346086 (10 mg/kg/day) for 2 weeks
Study: 12837854
Drug: CP-346086 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-346086 (single oral dose of 100 mg)
Study: 12837854
Drug: CP-346086 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-346086 (single oral dose of 1.3 mg/kg)
Study: 12837854
Drug: CP-346086 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-346086 (30 mg/day for 2 weeks)
Study: 8621785
Drug: L-arginine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (7 grams x 3/day)
Study: 1413587
Drug: UHF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: UHF therapy
Study: 3890140
Drug: Atropine (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (not specified dosage or duration)
Study: 3890140
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion without atropine
Study: 31915366
Drug: venetoclax +
Approvals — FDA: no, EMA: no, PMDA: no
Description: venetoclax + hypomethylating agent
Study: 18315507
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 300 mg three times a day for 6 months
Study: 15966876
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser treatment with wavelengths of 635 and 830 nm
Study: 7758260
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (60 U at 0 min)
Study: 7758260
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (120 U at 0 min)
Study: 7758260
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (60 U at 0 and +20 min)
Study: 7758260
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (120 U at +20 min)